GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Clinical trial NCT03751761 · COMPLETED

Trial details

NCT number: NCT03751761
Sponsor: Asan Medical Center
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Metastatic Gastric Cancer

Start date: 2018-06-11
Primary completion: 2023-08-30
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.